Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature.
Episodes of gout are common in the setting of renal transplantation. Hyperuricemia and gout have been associated with the use of the calcineurin inhibitor, cyclosporine. We report two cases of severe polyarticular gout resistant to conventional therapy in renal transplant recipients that resolved after switching from cyclosporine to tacrolimus-based immunosuppression. There was no alteration in renal function, and trough concentrations of both cyclosporine and tacrolimus were within the recommended range. Resolution of gout occurred within a month of discontinuation of cyclosporine and commencement of tacrolimus. Use of tacrolimus may be beneficial in the renal transplant recipient with refractory gout.
Pilmore
H L
HL
Department of Renal Medicine, Auckland Hospital, Park Road, Grafton, Auckland, New Zealand. hpilmore@adhb.gov.inz
Faire
B
B
Dittmer
I
I
D000328:Adult; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D006073:Gout / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood
D007166:Immunosuppressive Agents; D014527:Uric Acid; D016572:Cyclosporine; D016559:Tacrolimus